Structural insights for selective disruption of Beclin 1 binding to Bcl-2

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Autophagy stimulation holds therapeutic potential for diseases such as cancer and neurodegeneration.
• Bcl-2 is a key inhibitor of autophagy, binding to the Beclin 1 BH3-domain.
• Inhibiting Bcl-2 can promote autophagy but may also induce apoptosis by releasing pro-apoptotic factors like Bax.

Purpose of the Study:

• To elucidate the structural basis of compound 35's interaction with Bcl-2.
• To understand how compound 35 selectively inhibits Beclin 1/Bcl-2 binding over Bax/Bcl-2 binding.
• To guide the design of novel autophagy-stimulating therapeutics with reduced apoptotic side effects.

Main Methods:

• Nuclear Magnetic Resonance (NMR) spectroscopy was employed to determine the structure of Bcl-2 in complex with compound 35.
• Biochemical assays were used to compare the binding affinities of compound 35 to Beclin 1 and Bax.

Main Results:

• The NMR structure reveals that compound 35 binds to a distinct site on the BH3-binding groove of Bcl-2.
• Compound 35 demonstrates more potent inhibition of Beclin 1/Bcl-2 binding compared to Bax/Bcl-2 binding.
• The binding site for compound 35 partially overlaps with known Bcl-2 inhibitor sites but uniquely mediates interaction with Beclin 1.

Conclusions:

• Compound 35's unique binding mode provides a structural foundation for developing selective autophagy enhancers.
• Targeting the Beclin 1 interaction site on Bcl-2 offers a strategy to stimulate autophagy without inducing apoptosis.
• This research paves the way for designing safer and more effective therapies for autophagy-related diseases.